Avian Influenza Vaccine Market Trends

Avian Influenza Vaccine Market Overview

The Avian Influenza Vaccine market is anticipated to reach USD 1.18 Billion 2032 at a CAGR 7.5% during the forecast period 2024-2032. Avian influenza, also known as bird flu, is a viral infection that spreads from bird to bird and can infect other animals or humans also. There are different strains of avian influenza, causing the infection, but H5V1 is the most common virus strain affecting poultry animals.

October 2023: In the United Kingdom, the FluMap consortium led by the world’s most prominent experts in avian flu at Animal and Plant Health Agency found that Northern Gannets and Shag are showing signs of avian influenza immunity. The consortium received an additional US$3.8 million to fund research on bird flu transmission from disease spread remaining a threat.

April 2023: The U.S. Department of Agriculture (USDA) disclosed that it is testing a few vaccines against the current highly pathogenic avian influenza strain (HPAI) as part of its strategy to try preventing another episode if its worst-ever bird flu outbreak. There were four vaccine candidates being assessed by researchers with the U.S DA’s Agricultural Research Service (ARS), according to a spokesman for U.S. DA, who began in April with single-dose studies.

February 2023 - The United States Department of Agriculture (USDA) announces a grant program worth $10 million that will support research and development for better bird flu vaccines on poultry farms. The aim of this program is to create next-generation vaccine which will protect against various influenza strains.

February 2023 – Ceva launches its new CEVA FLU H5/H7 recombinant adenovirus vector vaccine for poultry, providing broad coverage against diverse subtypes of A influenza viruses.

February 2023- China reports successful DNA vaccination trials in chickens that could lead to more stable and scalable vaccine production methods.

September 2022: Wageningen Bioveterinary Research (WBVR) started an experiment with bird flu vaccination. Following laying hens being immunized with vaccines against existing H5 subtypes, this specific pilot study was performed inside WBNR’s animal facilities within its high containment unit. Developed by three different pharmaceutical companies, these state-of-the-art vaccines are based on different technologies.

Market Dynamics

The increasing strategic agreements are expected to drive market growth during the study period. For instance, in February 2018, the NC State College of Veterinary Medicine and Ceva Santé Animale, an animal health company, based in France, collaborated on a distance learning project providing certification in poultry health management for veterinarians in Latin America. Moreover, the increasing public & private initiatives by the government as well as non-government organizations for research & development are also anticipated to drive the market growth.

Avian Influenza Vaccine Market, by Strain, 2018 & 2025 (USD Million)

Source: MRFR Analysis

Segmentation

The Avian Influenza Vaccine Market has been segmented by strain and application. The market, based on strain, has been bifurcated into H5, H7, and H9. Based on application, the avian influenza vaccine market has been chicken, turkey, and goose & duck.

Africa Avian Influenza Vaccine Market Share, 2018 (%)

Source: MRFR Analysis

Regional Analysis

The Avian Influenza Vaccine Market, based on region, has been divided into the APAC & Middle East, Europe, Americas, and Africa.

The APAC & Middle East is likely to dominate the avian influenza vaccine market. This can be attributed to the increasing production of poultry birds and the rise in avian influenza outbreaks in the region. According to a recent report from the Foreign Agricultural Service/USDA, China recorded 13,800 thousand metric tons of chicken meat production in 2019. Furthermore, various government initiatives for rapid and effective response efforts to emergent zoonotic influenza viruses are also expected to drive market growth.

The European market for the avian influenza vaccine is estimated to be the second-largest during the review period. The growing dependence on poultry as the key source of protein in the diet in this region is expected to boost the growth of the regional market. According to the European Commission, the European Union (EU) produced 15.2 million tons of poultry meat in 2018. Additionally, increasing the production of veterinary products and improved animal husbandry practices in Germany and Poland are further fueling market growth.

Americas is estimated to demonstrate significant market growth owing to the growing meat & poultry industry, the increasing expenditure on animal health, and the presence of a large number of veterinary hospitals in the region. According to the North American Meat Institute, the US exported 3.7 million metric tons (MT) of poultry and poultry variety meats in 2017. The value was estimated at USD 4.5 billion. Moreover, growing government support for creating awareness on avian influenza viruses and improving efficiency for the avian influenza vaccine is also positively affecting the market growth.

Key Players

The Prominent Players in the Avian Influenza Vaccine Market are Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico), JOVAC (Jordan), and QYH BIOTECH COMPANY LIMITED (China). Some of the key strategies followed by players operating in the avian influenza vaccine market were collaborations, acquisition, product approval & launch, and expansion.

• In October 2019, Ceva and ProBioGen AG signed an exclusive license agreement for the manufacture of vectorized poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.

• In October 2018, Boehringer Ingelheim announced the opening of its biological research and development site in France. It invested USD 80.45 million (EUR 70 million) for maintaining its leading position in veterinary vaccines.

• In August 2017, Merck Animal Health announced the plans to purchase a new manufacturing facility in Austria. With this purchase, the company was intended to expand its global vaccine manufacturing capacity.

• In March 2016, Zoetis announced that the US Department of Agriculture (USDA) granted the company a conditional license for Avian Influenza Vaccine, H5N1 Subtype, and Killed Virus.

Market Segmentation

Avian Influenza Vaccine Market, by Strain

• H5


• H7


• H9

Avian Influenza Vaccine Market, by Application

• Chicken


• Turkey


• Duck & Goose

Avian Influenza Vaccine Market, by Region

• APAC & Middle East
  
  
  
  • China
  
  
  • Philippines
  
  
  • Vietnam
  
  
  • India
  
  
  • Bangladesh
  
  
  • Cambodia
  
  
  • Indonesia
  
  
  • Iran
  
  
  • Thailand
  
  
  • Pakistan
  
  
  • Rest of APAC & Middle East
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • Bulgaria
  
  
  • Poland
  
  
  • Hungary
  
  
  • Ukraine
  
  
  • Czech Republic
  
  
  • Rest of Europe
  
  
  
  


• Americas
  
  
  
  • US
  
  
  • Brazil
  
  
  • Mexico
  
  
  • Argentina
  
  
  • Columbia
  
  
  • Rest of the Americas
  
  
  
  


• Africa
  
  
  
  • South Africa
  
  
  • Nigeria
  
  
  • Ghana
  
  
  • Cameroon
  
  
  • Rest of Africa
  
  
  
  

Available Additional Customizations

• Challenges in the Avian Influenza Vaccine Market


• Investment Opportunities in the Avian Influenza Vaccine Market

Intended Audience

• Pharmaceutical companies


• Biotechnology companies


• Contract research organizations


• Research & development organizations


• Academic institutes